However, Moheet et al. found minimal effects of LUMA/IVA therapy on glucose metabolism only in patients with CF homozygous for the F508del CFTR mutation over 12 months, with no significant improvements in the majority of subjects, underscoring the heterogeneity across studies (15). Here, CFTR is linked to cystic fibrosis.